1. European Urology Oncology
Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer 
Henrik Olsson, Tobias Nordström, Mark Clements, Henrik Grönberg, Anna Wallerstedt Lantz, Martin Eklund 
European Urology Oncology 
DOI: /j.euo
Copyright © 2019 The Authors Terms and Conditions

2. Fig. 1
Flowchart of the study population. Low-risk PCa with AS indicated as the primary management option at diagnosis (AS cohort) and a second comparison group of low-risk PCa that did not undergo AS at diagnosis (non-AS group). AS=active surveillance; GS=Gleason score; NPCR=National Prostate Cancer Register; PCa=prostate cancer.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2019 The Authors Terms and Conditions

3. Fig. 2
Proportion of individuals with PSA/biopsy by time on AS in the AS cohort. Frequencies of PSA testing and biopsies are described as the yearly proportion of individuals with a repeat PSA and repeat biopsy during follow-up of 10yr. The horizontal reference lines represent the yearly recommended testing according to the national guidelines. AS=active surveillance; PSA=prostate-specific antigen.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2019 The Authors Terms and Conditions